Second-Cancer Signal Affirmed After Lenalidomide for Myeloma

Speaking on behalf of the investigators, Dr. Palumbo reported employment with, serving as a consultant and on the speakers bureau of, having equity ownership in, and receiving research funding, patent royalties, and honoraria from Celgene, maker of lenalidomide. Dr. Beksac reported honoraria and speakers bureau activity with Celgene and Janssen Cilag. Dr. Kristinsson reported no conflicts of interest.